Sagimet Biosciences (STU:0O2) Additional Paid-In Capital: €397.42 Mil(As of Mar. 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.64
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Additional Paid-In Capital?

Sagimet Biosciences STU:0O2 +2.15% 10 Additional Paid-In Capital is €397.42 Mil as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.


Sagimet Biosciences's quarterly additional paid-in capital increased from Sep. 2025 (€388.44 Mil) to Dec. 2025 (€390.80 Mil) and increased from Dec. 2025 (€390.80 Mil) to Mar. 2026 (€397.42 Mil).

Sagimet Biosciences's annual additional paid-in capital increased from Dec. 2023 (€312.49 Mil) to Dec. 2024 (€430.59 Mil) but then declined from Dec. 2024 (€430.59 Mil) to Dec. 2025 (€390.80 Mil).

Sagimet Biosciences Additional Paid-In Capital Related Terms

Sagimet Biosciences Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Additional Paid-In Capital Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial 29.30 33.04 312.49 430.59 390.80

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 418.43 393.58 388.44 390.80 397.42
STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of €397.42 Mil mean?
Sagimet Biosciences (STU:0O2) has a Additional Paid-In Capital of €397.42 Mil as of Mar. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' Additional Paid-In Capital too high?
Sagimet Biosciences' current Additional Paid-In Capital is €397.42 Mil. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Additional Paid-In Capital compare to EDIT and AUTL?
Sagimet Biosciences' Additional Paid-In Capital of €397.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Sagimet Biosciences and its competitors. Sagimet Biosciences's current Additional Paid-In Capital is €397.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Additional Paid-In Capital of €397.42 Mil. The current Additional Paid-In Capital is €397.42 Mil. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Additional Paid-In Capital is €397.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.64
Price